Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down – Here’s What Happened

Pacific Biosciences of California, Inc. (NASDAQ:PACB) gapped down before the market opened on Thursday. The stock had previously closed at $2.55, but opened at $2.24. Pacific Biosciences of California shares last traded at $2.6580, with a volume of 2,507,690 shares traded.

Key Stories Impacting Pacific Biosciences of California

Here are the key news stories impacting Pacific Biosciences of California this week:

• Positive Sentiment: For Q3 2026, PacBio reported a loss of $0.11 per share, better than the $0.13 loss analysts expected, while revenue of $40.56 million exceeded the $39.31 million consensus estimate. Zacks Q3 earnings report
• Positive Sentiment: A Q3 analysis pointed to clinical adoption and AI partnerships as contributors to steady growth, suggesting potential longer-term demand opportunities. Q3 clinical adoption and AI partnerships analysis
• Neutral Sentiment: PacBio narrowed its 2026 revenue guidance to $155 million–$160 million. A tighter range provides an updated outlook, but the article does not specify whether it represents a change in expected performance. Revenue guidance and cash-flow target
• Negative Sentiment: The company still posted a quarterly loss, and management is targeting cash-flow breakeven only in 2028, underscoring the time and execution required to reach sustainable finances. Cash-flow breakeven outlook

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on PACB shares. Weiss Ratings upgraded Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. Wall Street Zen cut Pacific Biosciences of California from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Piper Sandler reissued a “neutral” rating and issued a $3.00 target price (up from $2.00) on shares of Pacific Biosciences of California in a report on Thursday. Finally, UBS Group began coverage on shares of Pacific Biosciences of California in a research note on Wednesday, September 9th. They set a “neutral” rating and a $1.35 price target on the stock. One research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Reduce” and an average price target of $1.96.

Pacific Biosciences of California Trading Down 2.6%

The business has a 50 day moving average of $1.89 and a 200-day moving average of $1.62. The stock has a market cap of $771.79 million, a PE ratio of -5.78 and a beta of 2.21.

Pacific Biosciences of California (NASDAQ:PACB) last released its earnings results on Wednesday, November 4th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. The firm had revenue of $40.56 million for the quarter, compared to the consensus estimate of $39.31 million. Pacific Biosciences of California had a negative return on equity of 5,752.12% and a negative net margin of 82.49%. On average, equities research analysts anticipate that Pacific Biosciences of California, Inc. will post -0.52 EPS for the current fiscal year.

Insiders Place Their Bets

In other Pacific Biosciences of California news, insider James R. Gibson II sold 661,815 shares of Pacific Biosciences of California stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $3.11, for a total value of $2,058,244.65. Following the completion of the transaction, the insider owned 1,083,848 shares of the company’s stock, valued at $3,370,767.28. The trade was a 37.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Van Oene sold 26,911 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1.13, for a total value of $30,409.43. Following the transaction, the insider owned 2,705,853 shares of the company’s stock, valued at $3,057,613.89. This represents a 0.98% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 3.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in PACB. Hhlr Advisors LTD. bought a new position in Pacific Biosciences of California in the 2nd quarter valued at about $1,544,000. BlackRock Inc. bought a new position in Pacific Biosciences of California during the 2nd quarter valued at $54,330,000. Bank of America Corp DE acquired a new position in shares of Pacific Biosciences of California during the 2nd quarter valued at $2,265,000. Bank of New York Mellon Corp acquired a new position in shares of Pacific Biosciences of California during the 2nd quarter valued at $1,290,000. Finally, Man Group plc acquired a new position in shares of Pacific Biosciences of California during the 2nd quarter valued at $1,004,000.

About Pacific Biosciences of California

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.